The MDMA Therapy Training Program, maintained by MAPS Public Benefit Corporation (MAPS PBC), offers in-depth training into the practice of MDMA-assisted psychotherapy, with curriculum based on decades of clinical experience. Trainees learn the theoretical approach of the modality, developed from the fundamental notion that every person has within them an incredible source of wisdom and an innate ability to heal.

On December 20, 2019, the U.S. Food and Drug Administration (FDA) agreed to MAPS’ application for an Expanded Access program for MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD). The program’s purpose is to grant access to potentially beneficial investigational treatments for people facing a serious or immediately life-threatening condition for which there is no satisfactory treatment currently available.

MAPS PBC is currently conducting MDMA-assisted psychotherapy trials in the United States, Canada, Israel, the United Kingdom, and the European Union. While we are not actively recruiting new sites or therapists at this time, we are still accepting online applications for sites and providers who would like to be considered when opportunities open up in the future. The MDMA Therapy Training Program expects to open enrollment for the 2021 training year in the months ahead, at which point candidates who have an application on file will be reviewed and screened for enrollment. If you are interested in participating in the training program, please review the materials on this website, including the Application Requirements. Applicants who are affiliated with a site and a qualified therapy team will be prioritized so that we can better translate training resources into the most participants receiving treatment. Please sign up for emails on this page to receive updates on training opportunities for the MDMA Therapy Training Program.

MAPS’ Expanded Access protocol must still be approved by the U.S. Drug Enforcement Administration (DEA) and the Institutional Review Board (IRB). Based on the FDA’s review as well as the DEA and IRB’s existing support of MDMA-assisted psychotherapy clinical trials, MAPS does not anticipate delays in those approvals. The Phase 3 trials are expected to be completed in 2021, meaning that the FDA could approve the treatment as early as 2022.

The information below outlines the FDA Expanded Access program and the requirements for sites and therapy providers who are interested in conducting MDMA-assisted psychotherapy under a future MAPS MDMA PTSD protocol.



The basic requirements of a qualified site include: 1) Treatment Facility conducive to MDMA-assisted psychotherapy, 2) Therapy Team qualified and able to complete required training, made up of at least two therapy providers, and 3) Prescribing Physician who can obtain a DEA Schedule I license for MDMA.

Only sites in the U.S. and U.S. territories may participate in a U.S. FDA Expanded Access program. Over the coming years, as Phase 2 and 3 trials in Europe progress and additional protocols are developed and approved internationally, the MDMA Therapy Training Program plans to offer more training opportunities internationally. Each country has a unique set of regulations; many regions have programs similar to Expanded Access, sometimes called “Compassionate Use.” International programs may become available in the future.

For more information about the MDMA Therapy Training Program, please visit the MAPS Public Benefit Corporation (MAPS PBC) website or subscribe for email updates below.